Tumor cell-derived microvesicles
AssigneesThe Royal Institution for the Advancement of Learning/Mcgill University, University of Toronto
InventorsJanusz Rak, Khalid Al-Nedawi, Brian Meehan, Abhijit Guha
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for diagnosis of cancer and for monitoring the progression of cancer and/or the therapeutic efficacy of an anti-cancer treatment in a sample of a subject by detecting oncogenic proteins in microvesicles, and to the use of an agent blocking exchange of microvesicles for treating cancer.
Claims26
A method of detecting the presence of an oncogenic protein in a subject, comprising:
- collecting a sample from the subject;
- isolating microvesicles from the sample;
- and
- detecting the presence of the oncogenic protein in the microvesicles.
A method for monitoring progression of a cancer or therapeutic efficacy of an anti-cancer treatment in a subject, comprising:
- a) collecting a first sample from a subject having cancer at a first timepoint, isolating microvesicles from the first sample, and measuring an oncogenic protein in the microvesicles obtained from the first sample;
- and
- b) collecting a second sample from the subject having cancer at a second timepoint, the second timepoint occurring after the first timepoint, isolating microvesicles from the second sample, and measuring the oncogenic protein in the microvesicles obtained from the second sample;
- wherein a change in the amount of the oncogenic protein in the microvesicles obtained from the second sample compared to the amount of the oncogenic protein in the microvesicles obtained from the first sample is indicative of progression of the cancer, or a reduction or no change in the amount of the oncogenic protein in the microvesicles obtained from the second sample compared to the amount of the oncogenic protein in the microvesicles obtained from the first sample indicates therapeutic efficacy of the anti-cancer treatment when the first timepoint occurs before the subject has received an anti-cancer treatment, and the second timepoint occurs after the subject has received the anti-cancer treatment;
- and
- wherein said sample is a bodily fluid selected from the group consisting of blood, lymph, urine, cerebrospinal fluid, ascites, saliva, lavage, semen, glandular secretions, exudate, contents of cysts and feces.
(canceled)
(canceled)
(canceled)
-15. (canceled)
A kit for detecting a cancer in a sample from a subject comprising:
- at least one antibody against an oncogenic protein, and instructions for using said at least one antibody to detect the oncogenic protein in microvesicles in the sample.
(canceled)
(canceled)
(canceled)
-39. (canceled)
An isolated microvesicle comprising an oncogenic protein.
Dependencies are inferred from the claim text.